Patents Assigned to Concert Pharmaceuticals Inc.
  • SUBSTITUTED TRIAZOLOBENZODIAZEPINES
    Publication number: 20170258807
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 14, 2017
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Derivatives of pyrazole-substituted amino-heteroaryl compounds
    Patent number: 9707218
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: July 18, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Bhaumik A. Pandya, Craig E. Masse, Ian Robert Silverman, Roger D. Tung
  • Inhibitors of cholesterol ester transfer protein
    Patent number: 9708277
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 18, 2017
    Assignee: CONCERT PHARMACEUTICALS, INC.
    Inventor: Roger D. Tung
  • Substituted triazolobenzodiazepines
    Patent number: 9694017
    Abstract: This invention relates to novel substituted triazolobenzodiazepines of the Formula (I), wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Substituted thienotriazolodiazapines
    Patent number: 9676790
    Abstract: The present invention in one embodiment provides a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, wherein Y1, Y2 and Y3 are each independently selected from hydrogen and deuterium; R1, R2, and R3 are each methyl and are independently substituted with 0 to 3 deuterium; and R4 is t-butyl and is substituted with 0 to 9 deuterium; provided that if R1, R2 and R3 are each —CH3, and R4 is —C(CH3)3, then at least one of Y1 and Y2 is deuterium.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 13, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Morphinan compounds
    Patent number: 9655895
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 23, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d)-2,6-dione}
    Patent number: 9643950
    Abstract: The invention in one embodiment is directed to solid forms of {S-3-(4-Amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}, including an anhydrous crystalline form, two hydrates, and an amorphous form. The invention in one embodiment is directed to methods of preparation of the solid forms.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: May 9, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Joanna A. Bis, David H. Igo
  • Deuterated baricitinib
    Patent number: 9540367
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 10, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated momelotinib
    Patent number: 9518027
    Abstract: The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: December 13, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Robert Silverman
  • Deuterated CFTR potentiators
    Patent number: 9512079
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 6, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Adam J. Morgan
  • Substituted xanthine derivatives
    Patent number: 9493463
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 15, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Substituted xanthine derivatives
    Patent number: 9492457
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 15, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Synthesis of deuterated morpholine derivatives
    Patent number: 9453009
    Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: September 27, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
  • Deuterated ibrutinib
    Patent number: 9422295
    Abstract: The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: August 23, 2016
    Assignee: CONCERT PHARMACEUTICALS, INC.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Morphinan compounds
    Patent number: 9340512
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 17, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Substituted xanthine derivatives
    Patent number: 9328113
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: May 3, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Bhaumik Pandya, Scott L. Harbeson
  • Morphinan compounds
    Patent number: 9314440
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 19, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
    Patent number: 9315483
    Abstract: The present invention provides a convenient and efficient process for the synthesis of d2-benzo[d][1,3]dioxoles.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: April 19, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Andrew D. Jones, Robert E. Zelle, I. Robert Silverman
  • 4-hydroxybutyric acid analogs
    Patent number: 9309182
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: April 12, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Substituted isoindoline-1,3-dione derivatives
    Patent number: 9296689
    Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogs of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 29, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Julie F. Liu